

UK Modern Slavery Act Statement

Our UK Modern Slavery Act Statement provides information on the steps we have taken to eradicate slavery and human trafficking from our supply chain as well as within our own organization.

The Modern Slavery Act 2015 (the "Act") came into effect on 29 October 2015 and requires those entities carrying on a business or part of a business in the United Kingdom, supplying goods or services, and having annual turnover of £36 million or more, to disclose information regarding the steps they have taken to eradicate slavery and human trafficking from their supply chain as well as within their own organisation during the previous financial year.

We, Innova Medical Group, Inc., ("IMG") fully support the UK government's objectives to eradicate modern slavery and human trafficking and publish this Modern Slavery and Human Trafficking Statement, pursuant to section 54 of the Modern Slavery Act 2015, for the fiscal year ended 31 December 2021.

IMG is committed to good corporate citizenship and the highest ethical standards. Our approach reflects our commitment to acting ethically and with integrity in all our business relationships, helping to ensure that slavery and human trafficking is not taking place anywhere in our business. We expect all those in our supply chain to adopt a similar approach. To further fulfil these commitments, IMG has established and maintains systems and controls to safeguard against slavery and related human trafficking in the supply chain of products it purchases from suppliers. IMG does not manufacture products itself.

OUR BUSINESS

Innova Medical Group, Inc. delivers better global health outcomes with its deep expertise in testing and unique offerings in diagnostic medical devices and services that help tackle some of the world's most challenging healthcare problems. We specialize in innovative screening, testing and diagnostics for cancer, heart disease, arterial calcification, stroke, and virus detection focused on infectious diseases.

In response to the global pandemic, we have developed an end-to-end ecosystem of rapid diagnostic and screening tests, along with digital reporting and tracing applications to help organizations manage the COVID-19 crisis.

As a leader in the research and development of in-vitro diagnostic reagents and test kits, we have improved lives with testing, monitoring, and implementing medical care.

OUR VALUES, POLICIES, AND TRAINING

IMG is committed to sourcing quality products from suppliers who share its ethical values. Our Code of Conduct, provides important guidelines for IMG's interactions with customers, suppliers and other business partners, and between employees.

There are several principles that are central to the Code of Conduct. All employees are encouraged to raise concerns including potential violations of (i) the Code of Conduct; (ii)

company policies and (iii) the laws of the countries in which IMG operates. IMG has sophisticated reporting mechanisms in place to collect and relay information regarding potential violations to appropriate company resources for review and follow up.

IMG has policies which underpin our approach to tackling the risk of modern slavery in our supply chain, including, but not limited to, the whistleblowing provisions set out in the Code of Conduct which encourages employees to raise concerns including potential violations of (i) the Code of Conduct; (ii) company policies; and (iii) the laws of the countries in which IMG operates. IMG treats all concerns in good faith.

OUR SUPPLIERS AND THIRD-PARTY SERVICE PROVIDERS

We have relationships with suppliers and third-party service providers spanning the globe, delivering a wide variety of services and goods. Many of these third-party service providers have substantial and diverse supply chains of their own.

We are guided by principles, standards and associated governance structures for effectively identifying, assessing, monitoring, and mitigating risks associated with the use of third-party service providers. We are committed to act ethically and with integrity in our business dealings. To do so, we undergo extensive due diligence reviews of third-party service provider policies relating to, amongst other things, slavery and human trafficking. We expect our third-party service providers to adhere to the same high standards we set for our organization.

We supported suppliers during the pandemic by continuing to pay for orders promptly. We worked closely with suppliers throughout the period to source essential products and minimise interruptions in the supply to our customers.

We are continuously monitoring the situation and reviewing our existing measures in line with Government guidance. The Board of Directors has been kept up to date throughout the pandemic regarding risk levels and is actively involved in determining any adjustments that need to be made to existing measures.

APPROVAL

This statement has been approved by the Board of Directors.